About
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. The company is focused on developing new therapeutics for age-related degenerative disease. BioTime and its subsidiaries are developing OpRegen® (a cell-based therapy for age-related macular degeneration), therapies for cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics is using proprietary technology to reverse the developmental aging of human cells to manufacture young vascular progenitors for the treatment of age-related vascular disease. Relatively near-term product development by BioTime and its subsidiaries include Renevia, a patented hyaluronan-based hydrogel device for cell delivery; PanC-Dx, a blood-based pan-cancer screening diagnostic; and re-starting the embryonic stem cell-based clinical trial for spinal cord injury that was originally begun by Geron, using the stem cell assets acquired from them in 2013. BioTime als
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 57 investors are based in Carlsbad, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Carlsbad, US
Contact Information
Find more investors like Lineage
Search Investors